TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of epithelial ovarian or primary peritoneal cancer~* Measurable disease or evaluable disease with CA125 \>100~* One prior treatment with taxane/platinum based chemotherapy, but patients with recurrent ovarian cancer not receiving platinum-based chemotherapy at time of initial diagnosis will be allowed~* Recurrence after treatment free interval of at least 6 mos from completion of primary chemotherapy~* 19 years of age or older~* Life expectancy of greater than 12 weeks~* Performance status of 0, 1 or 2 (based on GOG Performance Status)~* Normal bone marrow, renal and hepatic function based upon lab tests~* Cardiac ejection fraction within institutional normal range~* Ability to swallow and retain oral medication~* Ability to understand a written informed consent document~Exclusion Criteria:~* Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering study~* Epithelial ovarian tumors of low malignant potential, stromal or germ cell origin~* Non-measurable or non-evaluable disease~* Archived tumor tissue not available for assay~* Patients may not be receiving any other investigational agents or concurrent anticancer therapy, or herbal (alternative) medicines~* Patients with known brain metastases~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent.~* Uncontrolled inter-current illness~* Patients who are pregnant~* HIV-positive patients receiving combination anti-retroviral therapy~* Patients with GI tract disease resulting in an inability to take oral medication

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Corticosteroids in Children With Cellulitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children Aged 1 month to 18 years~* Hospitalized due to cellulitis~* Patients who have given their written informed consent to participate~Exclusion Criteria:~* Skin chronic diseases~* Immunodeficiency (primary or acquired)~* Chronic use of systemic corticosteroids~* Sepsis~* Varicella~* History of adrenal insufficiency~* Pregnancy or breast feeding~* Uncontrolled diabetes mellitus~* Known hypersensitivity to systemic or topical corticosteroids~* Patient undergoing immunosuppressive therapy for another disease~* Participation in another drug biomedical research~* Any other contraindication for treatment with corticosteroids

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- CORTICOSTEROID (Type: EXPERIMENTAL): In addition to standard care for cellulitis, subject will receive intravenous Dexamethasone (8mg/2ml) 0.15 mg/kg/dose every 6 hours for the first 48 hours
- NORMAL SALINE (Type: PLACEBO_COMPARATOR): In addition to standard care for cellulitis, subject will receive normal saline solution administered intravenously using the same volume as the active drug group every 6 hours for the first 48 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be scheduled for a robotic LRP~* Patients must be between the ages of 35 and 75~* Patients must not have one of the listed exclusion criteria~* Patients must be able to understand and willing to adhere to the study protocol~* Patients must have a clinical stage diagnosis of T1 or T2~* Patients must have a preoperative serum PSA \< 20ng/ml~* Patients must have a biopsy Gleason score of 5-8~Exclusion Criteria:~* Patients less than 35 years of age and over 75 years of age.~* Patients with previous rectal surgery~* Patients with anal stenosis that prevents the TRUS probe insertion~* Patients with extensive abdominal surgery~* Patients with inadequate bowel prep~* Patients who are unwilling or unable to sign informed consent~* Patients on anticoagulation medication (eg. coumadin, lovenox, or heparin)~* Patients with a clinical stage diagnosis of T3 - Patients with a preoperative serum PSA ≥ 20 ng/mL~* Patients with a biopsy Gleason score \< 5 or \> 8

- Gender: MALE
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 3-D TRUS navigation software during T-RALP (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Soy Protein on Post- Breast Cancer Surgery Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women diagnosed with breast cancer and scheduled for elective breast cancer surgery (excluding breast biopsy) with axillary lymph node dissection (total and/or sentinel node excision).~* Women who are 21 years or older.~Exclusion Criteria:~* History of significant heart, gastro-intestinal, liver or kidney disease.~* Use of the anticoagulant, warfarin or Coumadin.~* Malabsorption of any kind.~* Diagnosed lactase deficiency.~* Known allergy to any of the tested dietary products.~* Basic daily consumption of soy protein in quantities exceeding 10 g/day.~* Women who are strict vegetarians (i.e. no animal derived dietary sources).~* The use of the following narcotics or adjuvant pharmacotherapy: opioids, anticonvulsants, antidepressants and steroids (except antidepressant use specifically for depression).~* Tumour size (if known) \> 3cm(i.e. size before pre-operative chemotherapy, if administered).~* Locally advanced breast cancer.~* Inflammatory breast cancer.~* Paget's disease of the breast with palpable mass.~* Suspected metastasis.~* Suspected micrometastasis.~* Previous breast surgery of any kind (except needle biopsy).~* The need for bilateral breast surgery.~* The existence of other known cancer, including metastasis, either in the other breast or elsewhere.~* Previous or current endocrine cancer therapy (e.g. selective estrogen receptor modulators, aromatase inhibitor).~* Body mass index (BMI) \> 35.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Soy protein (Type: EXPERIMENTAL): None
- Milk protein (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Study of IGIV, 10% in Alzheimer´s Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Completed 18 months of study treatment and assessments in Baxter precursor study 160701~* Diagnosis of probable Alzheimer´s Disease (AD)~* Able to comply with testing and infusion regimen (including adequate corrected visual acuity and hearing ability)~* Has a caregiver (study partner) who is willing and able to participate~Main Exclusion Criteria:~* Significant neurological disease other than AD~* Clinically significant cardiac/cardiovascular problems (e.g. uncontrolled blood pressure, atrial fibrillation, heart disease, clotting disorders, strokes, or recent heart attack)~* Contraindication to undergoing MRI (e.g. pacemaker \[with the exception of an MRI-compatible pacemaker\], severe claustrophobia, ferromagnetic implants such as a metal plate)~* Specific findings on brain MRI (microhemorrhages, superficial siderosis, vasogenic edema, a macrohemorrhage, major stroke, or multiple lacunae)~* Active malignancy or history of malignancy within 5 years prior to screening with the exception of the following: adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and stable prostate cancer not requiring treatment~* Uncontrolled major depression, psychosis, or other major psychiatric disorder(s)~* Poorly controlled diabetes~* Serious problems with liver or kidneys~* Known history of hypersensitivity following infusions of human blood or blood components (e.g. human immunoglobulins or human albumin)~* Current or recent treatment with immunomodulatory therapies (with the exception of immunoglobulin and non-systemic and low-dose systemic corticosteroids)~* Recent use of investigational drugs or biologics, including those aimed at altering AD progression (with the exception of immunoglobulin)~* Active immunization for the treatment of AD at any time~There are reasons why it might not be appropriate to participate in this trial. Please contact Medical Information at medinfo@baxter.com for details.

- Gender: ALL
- Minimum Age: 51 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IGIV, 10% at 0.2 g/kg body weight (Type: EXPERIMENTAL): IGIV, 10% at 0.2 g/kg body weight every 2 weeks for up to 3 years, 6 months.
- IGIV, 10% at 0.4 g/kg body weight (Type: EXPERIMENTAL): IGIV, 10% at 0.4 g/kg body weight every 2 weeks for up to 3 years, 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Post-menopausal stage I-III breast cancer patients~* Starting or about to start aromatase inhibitor~* English speaking with ability to read, write and use a computer to watch and listen to an educational module.~* Able to give informed consent~Exclusion Criteria:~* Aromatase inhibitor (AI) use for more than 6 months~* Metastatic breast cancer~* Non-English speaking, or unable to read, write or use a computer to watch and listen to an educational module.~* Unable to give informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Education and exercise intervention (Type: ACTIVE_COMPARATOR): The intervention module will contain a brief series of slides with a voice-over. An occupational therapist will review recommended exercises.
- Education and general exercise (Type: PLACEBO_COMPARATOR): The control module will contain a brief series of slides with a voice-over. A physical therapist with experience in treating breast cancer patients will demonstrate a series of 4-5 general stretching and toning exercises.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>/=18 to \</= 80 years of age.~2. Unresected and pathologically (histologic) proven Stage 3a or Stage 3b NSCLC of adenocarcinoma, squamous cell, large cell or mixed histology, diagnosed within three months of study randomization.~3. Non-metastatic disease staged by: CT-chest and upper abdomen, brain MRI or contrast-enhanced CT within 12 weeks and physical examination and whole body FDG-PET/CT scan within 8 weeks prior to study randomization.~Exclusion Criteria:~1. Eastern Cooperative Oncology Group (ECOG) performance status \>2.~2. More than 10% weight loss in the past 3 months.~3. Diabetic patient or anyone currently taking Metformin, insulin or other anti-hyperglycemic therapy.~4. Pulmonary Function Test (PFTs) (within the last 12 weeks) with Forced Expiratory Volume (FEV)1 \< 1.2 litres per second or less than 50% of predicted.~5. Complete Blood Count (CBC) and biochemical renal and liver function profiles that do not permit chemotherapy treatment (as per institutional standard of care).~6. Fasting blood sugar levels of \>/= 7.0 mmol per litre (within the last 12 weeks).~7. Prior systemic chemotherapy for lung cancer.~8. Prior radiotherapy that would overlap with the planned treatment area.~9. Prior invasive malignancy within the past 3 years (except non-melanomatous skin cancer non-invasive carcinoma in-situ of the breast, oral cavity or cervix).~10. Known Acquired Immune Deficiency Syndrome (AIDS).~11. Patients with increased risk for lactic acidosis:~    * severe congestive heart failure (NYHA: class III or IV),~   * history of metabolic acidosis,~   * alcoholic intake of \> 3 drinks daily,~   * severe liver disease,~   * renal failure~12. Known hypersensitivity or allergy to Metformin.~13. Known pregnancy or lactating female patient.~14. Geographic inaccessibility for follow-up.~15. Inability to provide informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Metformin plus Chemo-radiotherapy (Type: EXPERIMENTAL): Metformin orally 500 mg twice daily for the first week, 1500 mg a day in week 2 and 2000 mg a day at week 3 and then for a period of 12 months. Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
- Chemo-radiotherapy (Type: ACTIVE_COMPARATOR): Concurrent cisplatin based chemotherapy with or without consolidation and radiotherapy of 60-63 Gy for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patients must:~* Have relapsing remitting multiple sclerosis~* Have been on treatment with natalizumab for at least 6 months prior to screening and discontinuation is an option.~Exclusion Criteria:~Patients with:~* History of chronic immune disease~* Crohn's disease~* Certain cancers~* Uncontrolled diabetes~* Certain eye disorders~* Negative for varicella-zoster virus IgG antibodies~* Certain hepatic conditions~* Low white blood cell count~* On certain immunosuppressive medications or heart medications~* Resting heart rate less than 45 bpm.~* Certain heart conditions or certain lung conditions~* Inability to undergo MRI scans~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 8-week washout + Fingolimod (FTY720) (Type: EXPERIMENTAL): 8-week washout (8 weeks no treatment) followed by 24 weeks of treatment with fingolimod 0.5mg once a day
- 12-week washout + Fingolimod (FTY720) (Type: EXPERIMENTAL): 12-week washout (8 weeks no treatment and 4 weeks placebo) followed by 20 weeks of treatment with fingolimod 0.5mg once a day
- 16-week washout + Fingolimod (FTY720) (Type: EXPERIMENTAL): 16-week washout (8 weeks no treatment and 8 weeks placebo) followed by 16 weeks of treatment with fingolimod 0.5mg once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Ear Drops for Children With Acute Otitis Media

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 1 to 6 years~* Parent-reported ear pain in 24 hours prior to enrolment~* GP-diagnosis of (uni- or bilateral) AOM~Exclusion Criteria:~* with (suspected) tympanic membrane perforation or ventilation tubes~* with ear wax obscuring visualisation of the tympanic membrane~* who are systemically very unwell or require hospital admission (e.g. child has signs and symptoms of serious illness and/or complications such as mastoiditis/meningitis)~* who are at high risk of serious complications including children with known immunodeficiency other than partial IgA or IgG2 deficiencies, craniofacial malformation including cleft palate, Down syndrome and previous ear surgery (with the exception of ventilation tubes in the past)~* who have a known allergy or sensitivity to study medication or similar substances (e.g. other amide-type anaesthetics: bupivacaine, mepivacaine, prilocaine, etc)~* who have taken part in any research involving medicines within the last 90 days, or any other AOM-related research within the last 30 days~* who suffer from chronic recurrent pain of another origin than the ear~* who have participated in this trial during prior AOM episode

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine ear drops with usual care (Type: EXPERIMENTAL): usual care: oral analgesic with/without antibiotics
- usual care (Type: NO_INTERVENTION): usual care: oral analgesic with/without antibiotics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants provide signed written informed consent prior to perform any study-related activity~* Participants has completed the long-term extension of the reSURFACE 2 study~Exclusion Criteria:~* Participants unable to comply with the requirements of the study~* Participants who in the opinion of the investigator should not participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tildrakizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Psychophysiological Study of Pain Perception in Depressed Patients With Suicidal Risk

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria for all patients:~* Woman;~* Being aged between 18 and 65 years;~* Currently meeting the DSM-5 major depressive episode criteria;~* Being able to understand the nature, purpose and methodology of the study and agreeing to cooperate during the assessments;~* Having signed informed consent;~* Being affiliated with a social security or equivalent.~Inclusion Criteria specific to each group:~* Recent attempters: women having recently attempted suicide (less than 72 hours)~* Past attempters: women having a past suicide attempt (more than 72 hours)~* Affective control: women without lifetime history of suicidal behaviour (affective control group).~Exclusion Criteria for all patients:~* Existence of current psychotic or mixed characteristics;~* Lifetime history of schizoaffective disorder or schizophrenia;~* Current substance dependence (within the last 6 months);~* Existence of mental retardation or serious medical comorbidity interfering with measures (HIV, diabetes, cancer, chronic inflammatory pathology, neurological disorder);~* Having taken painkillers within the last 24 hours preceding the evaluation;~* Existence of a usual or current treatment with analgesics or NSAIDs (daily analgesic treatment more than 3 months);~* Existence of a sensory or cognitive handicap;~* Pregnant or lactating woman.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Major Depressive patients (Type: EXPERIMENTAL): 3 groups:~* Women having recently attempted suicide (less than 72 hours).~* Women having a past suicide attempt (more than 72 hours).~* Women without lifetime history of suicidal behaviour.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: South Miami Hospital Fibroid Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients seeking treatment for uterine myomas, leiomyomas, or fibromas.~2. Patients between the ages of 18-89.~3. Patients that agree to participate and sign consent.~Exclusion Criteria:~1)Patients that decline to participate and/or are younger than 18 or older than 89.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval